BRIEF published on 07/28/2026 at 08:05, 1 month 15 days ago TRILOGIQ publishes its annual consolidated financial statements PEA-PME Euronext Growth Financial Transparency Annual Accounts TRILOGIQ
BRIEF published on 07/28/2026 at 08:05, 1 month 15 days ago TRILOGIQ publie ses comptes consolidés annuels PEA-PME Euronext Growth Transparence Financière Comptes Annuels TRILOGIQ
PRESS RELEASE published on 07/28/2026 at 08:00, 1 month 15 days ago TRILOGIQ - Comptes consolidés annuels au 31 mars 2026 Les comptes consolidés annuels de TRILOGIQ au 31 mars 2026 sont disponibles sur les sites internet de TRILOGIQ et de Euronext Growth. TRILOGIQ - ISIN FR0010397901-MNEMONIQUE : ALTRI. TRILOGIQ est éligible au PEA-PME PEA-PME Euronext Growth Comptes Consolidés TRILOGIQ
BRIEF published on 01/21/2026 at 08:05, 7 months 22 days ago TRILOGIQ: Publication of consolidated half-year financial statements PEA-PME Investors Euronext Growth TRILOGIQ Half-year Accounts
BRIEF published on 01/21/2026 at 08:05, 7 months 22 days ago TRILOGIQ : Publication des comptes semestriels consolidés PEA-PME Euronext Growth Investisseurs TRILOGIQ Comptes Semestriels
PRESS RELEASE published on 01/21/2026 at 08:00, 7 months 22 days ago TRILOGIQ - Comptes consolidés semestriels au 30 septembre 2025 Les comptes consolidés semestriels de TRILOGIQ au 30 septembre 2025 sont disponibles sur les sites internet de TRILOGIQ et Euronext Growth. TRILOGIQ est éligible au PEA-PME PEA-PME Euronext Growth Comptes Consolidés TRILOGIQ 30 Septembre 2025
BRIEF published on 07/24/2025 at 08:05, 1 year 1 month ago TRILOGIQ : Bilan annuel 2025 et perspectives Chiffre D'affaires Marge Brute Carnet De Commandes Perspectives 2025 TRILOGIQ Finances
BRIEF published on 07/24/2025 at 08:05, 1 year 1 month ago TRILOGIQ: 2025 Annual Review and Outlook Gross Margin Order Book Turnover Outlook 2025 TRILOGIQ Finances
PRESS RELEASE published on 07/24/2025 at 08:00, 1 year 1 month ago TRILOGIQ - Comptes consolidés annuels au 31 mars 2025 Trilogiq publie ses comptes consolidés annuels au 31 mars 2025, avec un chiffre d'affaires de 23.203 K€ et un excédent brut d'exploitation de 1.223 K€, marqués par une légère baisse et une optimisation des coûts Chiffre D'affaires Baisse Comptes Consolidés Excédent Brut D'Exploitation TRILOGIQ
BRIEF published on 01/20/2025 at 08:35, 1 year 7 months ago TRILOGIQ: Half-year results up as of September 30, 2024 Financial Results Growth Turnover Standardization TRILOGIQ
Published on 09/12/2026 at 02:35, 14 hours 52 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 18 hours 27 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 19 hours 22 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 20 hours 2 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 1 day ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 9 hours 56 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 19 hours 11 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 19 hours 16 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 21 hours 42 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 23 hours 11 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 10 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 10 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 21 hours ago Availability of the 2026 Interim Financial Report
